董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lawrence Steinman | 男 | Executive Chairman and Co-Founder | 75 | 25.00万美元 | 未持股 | 2023-10-26 |
| Simon Dumesnil | 男 | Director | 46 | 6.00万美元 | 未持股 | 2023-10-26 |
| Tiago Reis Marques | 男 | Chief Executive Officer and Director | 47 | 53.93万美元 | 未持股 | 2023-10-26 |
| Emer Leahy | 女 | Director | 57 | 6.00万美元 | 未持股 | 2023-10-26 |
| Alfred Novak | 男 | Director | 75 | 6.36万美元 | 未持股 | 2023-10-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lawrence Steinman | 男 | Executive Chairman and Co-Founder | 75 | 25.00万美元 | 未持股 | 2023-10-26 |
| Daniel Schneiderman | 男 | Chief Financial Officer | 45 | 36.72万美元 | 未持股 | 2023-10-26 |
| Tiago Reis Marques | 男 | Chief Executive Officer and Director | 47 | 53.93万美元 | 未持股 | 2023-10-26 |
| Daniel Schneiderman | 男 | Chief Financial Officer | 45 | 未披露 | 未持股 | 2023-10-26 |
| Graeme Currie | 男 | Chief Development Officer | 57 | 未披露 | 未持股 | 2023-10-26 |
董事简历
中英对照 | 中文 | 英文- Lawrence Steinman
-
Lawrence Steinman曾于2016年4月至2020年7月担任BioAtla，LLC的顾问委员会成员，并自2020年7月起担任董事会成员。此前，Steinman博士于2014年4月至2016年5月担任科学顾问。他是斯坦福大学（Stanford University）的神经病学和神经科学、儿科和遗传学教授，在那里他自1980年以来一直担任教授。Steinman博士的研究专注于多发性硬化症（MS）复发和缓解的原因，多发性硬化症是一种抑制脑炎的分子，也是寻找自身免疫性疾病疫苗的关键。迄今为止，Steinman博士已经为MS和1型糖尿病开发了两种抗原特异性疗法，使用DNA疫苗。具体而言，Steinman博士实验室的研究导致了药物Tysabri Natalizumab的开发，该药物用于治疗克罗恩病患者。他的研究获得了许多奖项，并当选为美国国家科学院和美国国家医学科学院院士。Steinman博士于2012年1月至2019年8月担任Atreca，Inc.的董事会成员，该公司是一家生物技术公司，专注于开发用于癌症治疗的新型疗法。Steinman博士在达特茅斯学院（Dartmouth College）获得学士学位，在哈佛大学（Harvard University）获得医学博士学位。
Lawrence Steinman,as served as Co-Executive Chairman since the Closing of the Business Combination in November 2020. He also has primary scientific responsibility for 180 Life Sciences Corp. α7nAChR platform. Dr. Steinman served as Co-Chairman of 180 and as a member of its board of directors since April 2019. Prior to joining 180, he served on the Board of Directors of Centocor Biotech, Inc., from 1989 to 1998, the Board of Directors of Neurocine Biosciences from 1997 to 2005, the Board of Directors of Atreca from 2010 – 2019, the Board of Directors of BioAtla, Inc. (NASDAQ:BCAB) from July 2020 to present (he also serves on the Compensation Committee and Nominating and Corporate Governance Committee of BioAtla), the Board of Directors of Tolerion, Inc. from 2013 to 2020 and the Board of Directors of Alpha5 Integrin from November 2020 to June 2022, and the Board of Directors of Pasithea Therapeutics Corp. (NASDAQ:KTTA) from August 2020 to the present. He is currently the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University and previously served as the Chair of the Interdepartmental Program in Immunology at Stanford University Medical School from 2003 to 2011. He is a member of the National Academy of Medicine and the National Academy of Sciences. He also founded the Steinman Laboratory at Stanford University, which is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. He received the Frederic Sasse Award from the Free University of Berlin in 1994, the Sen. Jacob Javits Award from the U.S. Congress from 1988 through 2002, the John Dystel Prize in 2004 from the National MS Society in the U.S., the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011 from the International Federation of MS Societies and the Anthony Cerami Award in Translational Medicine by the Feinstein Institute of Molecular Medicine in 2015. In 2023, he was honored as a Pioneer in Medicine by the Society for Brain Mapping and Therapeutics. He also received an honorary Ph.D. from the Hasselt University in 2008, and from the University of Buenos Aires in 2022. He received his BA (physics) from Dartmouth College in 1968 and his MD from Harvard University in 1973. He also completed a fellowship in chemical immunology at the Weizmann Institute (1974 – 1977) and was an intern and resident at Stanford University Medical School. - Lawrence Steinman曾于2016年4月至2020年7月担任BioAtla，LLC的顾问委员会成员，并自2020年7月起担任董事会成员。此前，Steinman博士于2014年4月至2016年5月担任科学顾问。他是斯坦福大学（Stanford University）的神经病学和神经科学、儿科和遗传学教授，在那里他自1980年以来一直担任教授。Steinman博士的研究专注于多发性硬化症（MS）复发和缓解的原因，多发性硬化症是一种抑制脑炎的分子，也是寻找自身免疫性疾病疫苗的关键。迄今为止，Steinman博士已经为MS和1型糖尿病开发了两种抗原特异性疗法，使用DNA疫苗。具体而言，Steinman博士实验室的研究导致了药物Tysabri Natalizumab的开发，该药物用于治疗克罗恩病患者。他的研究获得了许多奖项，并当选为美国国家科学院和美国国家医学科学院院士。Steinman博士于2012年1月至2019年8月担任Atreca，Inc.的董事会成员，该公司是一家生物技术公司，专注于开发用于癌症治疗的新型疗法。Steinman博士在达特茅斯学院（Dartmouth College）获得学士学位，在哈佛大学（Harvard University）获得医学博士学位。
- Lawrence Steinman,as served as Co-Executive Chairman since the Closing of the Business Combination in November 2020. He also has primary scientific responsibility for 180 Life Sciences Corp. α7nAChR platform. Dr. Steinman served as Co-Chairman of 180 and as a member of its board of directors since April 2019. Prior to joining 180, he served on the Board of Directors of Centocor Biotech, Inc., from 1989 to 1998, the Board of Directors of Neurocine Biosciences from 1997 to 2005, the Board of Directors of Atreca from 2010 – 2019, the Board of Directors of BioAtla, Inc. (NASDAQ:BCAB) from July 2020 to present (he also serves on the Compensation Committee and Nominating and Corporate Governance Committee of BioAtla), the Board of Directors of Tolerion, Inc. from 2013 to 2020 and the Board of Directors of Alpha5 Integrin from November 2020 to June 2022, and the Board of Directors of Pasithea Therapeutics Corp. (NASDAQ:KTTA) from August 2020 to the present. He is currently the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University and previously served as the Chair of the Interdepartmental Program in Immunology at Stanford University Medical School from 2003 to 2011. He is a member of the National Academy of Medicine and the National Academy of Sciences. He also founded the Steinman Laboratory at Stanford University, which is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. He received the Frederic Sasse Award from the Free University of Berlin in 1994, the Sen. Jacob Javits Award from the U.S. Congress from 1988 through 2002, the John Dystel Prize in 2004 from the National MS Society in the U.S., the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011 from the International Federation of MS Societies and the Anthony Cerami Award in Translational Medicine by the Feinstein Institute of Molecular Medicine in 2015. In 2023, he was honored as a Pioneer in Medicine by the Society for Brain Mapping and Therapeutics. He also received an honorary Ph.D. from the Hasselt University in 2008, and from the University of Buenos Aires in 2022. He received his BA (physics) from Dartmouth College in 1968 and his MD from Harvard University in 1973. He also completed a fellowship in chemical immunology at the Weizmann Institute (1974 – 1977) and was an intern and resident at Stanford University Medical School.
- Simon Dumesnil
-
Simon Dumesnil自2021年4月以来一直在我们的董事会任职。他目前是Dunraven Capital Partners Limited的管理合伙人和董事，这是一家在英国注册成立的投资管理咨询公司，其投资主要是东欧企业不良贷款和结构性产品。从2013年到2018年，Dumesnil先生担任瑞银证券有限责任公司（UBS Securities LLC）的董事总经理兼结构融资集团美洲负责人，在那里他负责美国和LATAM的结构性融资交易，并管理固定收益产品公司辛迪加和中间市场贷款，公司债券，房地产贷款，CMBS/RMBS/CLO/ABS，LATAM Sovereign的融资头寸。从2010年到2013年，他曾担任UBS AG.的私人侧结构化集团EMEA的董事总经理兼联席主管，在那里他曾负责安排FIG和特殊情况集团（SSG）的结构化解决方案交易和收购，也曾共同领导非流动性融资业务。从2009年到2010年，Dumesnil先生担任Bluestone Capital Management的首席投资官，负责欧洲各地不良资产的投资。从2008年到2009年，Dumesnil先生是Lehman Brother Holding Inc.的董事，负责重组和解散Lehman Brothers Special Financing Inc.。从2003年到2008年，Dumesnil先生是Lehman Brothers International（欧洲）的董事。在Dunraven Capital Management，UBS Securities，UBS AG，Bluestone Capital Management和Lehman Brothers的整个职业生涯中，Dumesnil先生为跨行业或司法管辖区的公司提供咨询和承销公司风险。他对公司重组和资本结构优化有深入的了解，涉及公司的整个业务生命周期。他在一家金融服务和科技公司成立和成长阶段担任首席投资官的经验，代表了我们公司的宝贵见解。他在卡斯商学院（Cass Business School）和Cole des Hautes-É；Tudes-Commerciales HEC获得了银行和国际金融理学硕士学位，在那里他获得了商业和管理学士学位，金融。
Simon Dumesnil has served on our board of directors since April 2021. He is currently a Managing Partner and Director of Dunraven Capital Partners Limited, an investment management advisory company incorporated in the UK whose investments are predominately in Eastern European corporate distressed credits and structured products. From 2013 to 2018 Mr. Dumesnil was Managing Director and Head of Structured Financing Group Americas of UBS Securities LLC, where he was responsible for the structured financing trading book in the USA and LATAM and managed a book of financing positions across fixed income products corporate syndicated and middle-market loans, corporate bonds, real estate loans, CMBS/RMBS/CLO/ABS, LATAM Sovereign. From 2010 to 2013 he was Managing Director and Co-Head Private-Side Structuring Group EMEA of UBS AG., where he was responsible for arranging structured solution transactions and acquisitions for FIG and Special Situation Group (SSG) and also co-headed the illiquid financing business. From 2009 to 2010 Mr. Dumesnil was the Chief Investment Officer Bluestone Capital Management and responsible for investments in distressed assets across Europe. From 2008 to 2009 Mr. Dumesnil was Director of Lehman Brother Holding Inc. and responsible for restructuring and unwinding Lehman Brothers Special Financing Inc. derivative book post-bankruptcy. From 2003 to 2008 Mr. Dumesnil was Director of Lehman Brothers International (Europe). Throughout his career at Dunraven Capital Management, UBS Securities, UBS AG, Bluestone Capital Management and Lehman Brothers, Mr. Dumesnil advised and underwritten corporate risk related to companies across industries or jurisdictions. He has an in-depth knowledge on corporate restructuring and capital structure optimization for companies across their business life cycle. His experience as Chief Investment Officer during the launch and growth phases of a financial services and technology company represents valuable insights for our Company. Mr. Dumesnil attended Cass Business School, where he received his Master of Science in Banking and International Finance and École des Hautes-Études-Commerciales HEC, where he received his Bachelor in Business and Administration, Finance. - Simon Dumesnil自2021年4月以来一直在我们的董事会任职。他目前是Dunraven Capital Partners Limited的管理合伙人和董事，这是一家在英国注册成立的投资管理咨询公司，其投资主要是东欧企业不良贷款和结构性产品。从2013年到2018年，Dumesnil先生担任瑞银证券有限责任公司（UBS Securities LLC）的董事总经理兼结构融资集团美洲负责人，在那里他负责美国和LATAM的结构性融资交易，并管理固定收益产品公司辛迪加和中间市场贷款，公司债券，房地产贷款，CMBS/RMBS/CLO/ABS，LATAM Sovereign的融资头寸。从2010年到2013年，他曾担任UBS AG.的私人侧结构化集团EMEA的董事总经理兼联席主管，在那里他曾负责安排FIG和特殊情况集团（SSG）的结构化解决方案交易和收购，也曾共同领导非流动性融资业务。从2009年到2010年，Dumesnil先生担任Bluestone Capital Management的首席投资官，负责欧洲各地不良资产的投资。从2008年到2009年，Dumesnil先生是Lehman Brother Holding Inc.的董事，负责重组和解散Lehman Brothers Special Financing Inc.。从2003年到2008年，Dumesnil先生是Lehman Brothers International（欧洲）的董事。在Dunraven Capital Management，UBS Securities，UBS AG，Bluestone Capital Management和Lehman Brothers的整个职业生涯中，Dumesnil先生为跨行业或司法管辖区的公司提供咨询和承销公司风险。他对公司重组和资本结构优化有深入的了解，涉及公司的整个业务生命周期。他在一家金融服务和科技公司成立和成长阶段担任首席投资官的经验，代表了我们公司的宝贵见解。他在卡斯商学院（Cass Business School）和Cole des Hautes-É；Tudes-Commerciales HEC获得了银行和国际金融理学硕士学位，在那里他获得了商业和管理学士学位，金融。
- Simon Dumesnil has served on our board of directors since April 2021. He is currently a Managing Partner and Director of Dunraven Capital Partners Limited, an investment management advisory company incorporated in the UK whose investments are predominately in Eastern European corporate distressed credits and structured products. From 2013 to 2018 Mr. Dumesnil was Managing Director and Head of Structured Financing Group Americas of UBS Securities LLC, where he was responsible for the structured financing trading book in the USA and LATAM and managed a book of financing positions across fixed income products corporate syndicated and middle-market loans, corporate bonds, real estate loans, CMBS/RMBS/CLO/ABS, LATAM Sovereign. From 2010 to 2013 he was Managing Director and Co-Head Private-Side Structuring Group EMEA of UBS AG., where he was responsible for arranging structured solution transactions and acquisitions for FIG and Special Situation Group (SSG) and also co-headed the illiquid financing business. From 2009 to 2010 Mr. Dumesnil was the Chief Investment Officer Bluestone Capital Management and responsible for investments in distressed assets across Europe. From 2008 to 2009 Mr. Dumesnil was Director of Lehman Brother Holding Inc. and responsible for restructuring and unwinding Lehman Brothers Special Financing Inc. derivative book post-bankruptcy. From 2003 to 2008 Mr. Dumesnil was Director of Lehman Brothers International (Europe). Throughout his career at Dunraven Capital Management, UBS Securities, UBS AG, Bluestone Capital Management and Lehman Brothers, Mr. Dumesnil advised and underwritten corporate risk related to companies across industries or jurisdictions. He has an in-depth knowledge on corporate restructuring and capital structure optimization for companies across their business life cycle. His experience as Chief Investment Officer during the launch and growth phases of a financial services and technology company represents valuable insights for our Company. Mr. Dumesnil attended Cass Business School, where he received his Master of Science in Banking and International Finance and École des Hautes-Études-Commerciales HEC, where he received his Bachelor in Business and Administration, Finance.
- Tiago Reis Marques
-
Tiago Reis Marques自2020年8月起担任我们的董事会成员和首席执行官。他是伦敦帝国理工学院（Imperial College London）的高级临床研究员，伦敦大学国王学院（King&s College London）的讲师。IPPN在心理学和精神病学方面被《美国新闻》（US News）和最佳全球大学评为全球第二，是世界上最大的神经科学研究中心之一。Marques医生也是莫德斯利医院的精神病学家。他的研究主要集中在精神药物的作用机制和新的治疗靶点。在他的职业生涯中，他的研究获得了多个奖项。Marques博士是精神病学和神经科学同行评审期刊上100多种科学出版物的作者或合著者，曾合著国际治疗指南和著作章节，包括该领域的领先著作《精神疾病的神经生物学》。”.
Tiago Reis Marques has served on our board of directors and as Chief Executive Officer since August 2020. He is a senior clinical fellow at Imperial College London and a lecturer at the IoPPN, King’s College London. IoPPN is ranked second in the world for psychology and psychiatry by US News and Best Global Universities, and is home to one of the world’s largest centers for neuroscience research. Dr. Marques is also a psychiatrist at Maudsley Hospital. His research focuses on topics including the mechanism of action of psychiatric medication and novel treatment targets. During his career, he has obtained multiple awards for his research. Dr. Marques is an author or co-author of more than 100 scientific publications in peer-reviewed journals in psychiatry and neuroscience, has co-authored international treatment guidelines and written book chapters, including in the leading book in the field, “Neurobiology of Mental Illness.”. - Tiago Reis Marques自2020年8月起担任我们的董事会成员和首席执行官。他是伦敦帝国理工学院（Imperial College London）的高级临床研究员，伦敦大学国王学院（King&s College London）的讲师。IPPN在心理学和精神病学方面被《美国新闻》（US News）和最佳全球大学评为全球第二，是世界上最大的神经科学研究中心之一。Marques医生也是莫德斯利医院的精神病学家。他的研究主要集中在精神药物的作用机制和新的治疗靶点。在他的职业生涯中，他的研究获得了多个奖项。Marques博士是精神病学和神经科学同行评审期刊上100多种科学出版物的作者或合著者，曾合著国际治疗指南和著作章节，包括该领域的领先著作《精神疾病的神经生物学》。”.
- Tiago Reis Marques has served on our board of directors and as Chief Executive Officer since August 2020. He is a senior clinical fellow at Imperial College London and a lecturer at the IoPPN, King’s College London. IoPPN is ranked second in the world for psychology and psychiatry by US News and Best Global Universities, and is home to one of the world’s largest centers for neuroscience research. Dr. Marques is also a psychiatrist at Maudsley Hospital. His research focuses on topics including the mechanism of action of psychiatric medication and novel treatment targets. During his career, he has obtained multiple awards for his research. Dr. Marques is an author or co-author of more than 100 scientific publications in peer-reviewed journals in psychiatry and neuroscience, has co-authored international treatment guidelines and written book chapters, including in the leading book in the field, “Neurobiology of Mental Illness.”.
- Emer Leahy
-
Emer Leahy，自2016年6月起担任Intensity Therapeutics，Inc.董事会董事。Leahy博士在爱尔兰都柏林大学学院获得神经药理学博士学位，在哥伦比亚大学获得MBA学位。自2000年以来，她一直担任PsychoGenics Inc.的首席执行官，这是一家盈利的临床前CNS服务公司。她还是PGI Drug Discovery LLC的首席执行官，该公司从事精神药物发现，有五个合作临床项目，其中一个处于第三阶段。此外，她还在西奈山医学院担任神经科学兼职副教授。Leahy博士在制药和生物技术公司的药物发现、临床开发和业务发展方面拥有30多年的经验，包括广泛的技术评估、许可、并购和战略规划方面的知识。Leahy博士曾在生物技术产业组织（BIO）董事会的新兴公司科理事会、阿尔茨海默氏症药物发现基金会的商业审查委员会和国际雷特综合症基金会的科学咨询委员会任职。她目前还担任PsychoGenics公司、Bright Minds生物科学公司、Pasithea治疗公司和BIONJ公司董事会的董事。
Emer Leahy,has served on Intensity Therapeutics, Inc. board of directors since June 2016. Dr. Leahy received her Ph.D. in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. Since 2000, she has served as CEO of PsychoGenics Inc., a profitable preclinical CNS service company. She is also CEO of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with five partnered clinical programs including one in Phase 3. Further, she holds an Adjunct Associate Professor of Neuroscience position at Mount Sinai School of Medicine. Dr. Leahy has more than 30 years of experience in drug discovery, clinical development and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. Dr. Leahy served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization (BIO), the Business Review Board for the Alzheimer's Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She also currently serves on the Board of Directors of PsychoGenics Inc., Bright Minds Biosciences, Pasithea Therapeutics, and on the Board of Trustees of BIONJ. - Emer Leahy，自2016年6月起担任Intensity Therapeutics，Inc.董事会董事。Leahy博士在爱尔兰都柏林大学学院获得神经药理学博士学位，在哥伦比亚大学获得MBA学位。自2000年以来，她一直担任PsychoGenics Inc.的首席执行官，这是一家盈利的临床前CNS服务公司。她还是PGI Drug Discovery LLC的首席执行官，该公司从事精神药物发现，有五个合作临床项目，其中一个处于第三阶段。此外，她还在西奈山医学院担任神经科学兼职副教授。Leahy博士在制药和生物技术公司的药物发现、临床开发和业务发展方面拥有30多年的经验，包括广泛的技术评估、许可、并购和战略规划方面的知识。Leahy博士曾在生物技术产业组织（BIO）董事会的新兴公司科理事会、阿尔茨海默氏症药物发现基金会的商业审查委员会和国际雷特综合症基金会的科学咨询委员会任职。她目前还担任PsychoGenics公司、Bright Minds生物科学公司、Pasithea治疗公司和BIONJ公司董事会的董事。
- Emer Leahy,has served on Intensity Therapeutics, Inc. board of directors since June 2016. Dr. Leahy received her Ph.D. in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. Since 2000, she has served as CEO of PsychoGenics Inc., a profitable preclinical CNS service company. She is also CEO of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with five partnered clinical programs including one in Phase 3. Further, she holds an Adjunct Associate Professor of Neuroscience position at Mount Sinai School of Medicine. Dr. Leahy has more than 30 years of experience in drug discovery, clinical development and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. Dr. Leahy served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization (BIO), the Business Review Board for the Alzheimer's Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation. She also currently serves on the Board of Directors of PsychoGenics Inc., Bright Minds Biosciences, Pasithea Therapeutics, and on the Board of Trustees of BIONJ.
- Alfred Novak
-
Alfred Novak，自2022年9月起担任Pasithea Therapeutics Corp.董事会成员。作为首席执行官和首席财务官，诺瓦克先生拥有丰富的运营经验，曾在多家制药和医疗设备公司的董事会任职。诺瓦克在产品开发、监管审批、商业活动等方面拥有敏锐的财务头脑和广泛的专业知识，并在为股东创造可观价值方面拥有良好的记录。2015年10月至2022年6月，诺瓦克先生担任LivaNova公司（纳斯达克股票代码：LIVN）的董事，该公司是一家医疗设备公司。从2017年5月到2019年11月，诺瓦克担任Dova制药的董事，该公司以超过9亿美元的价格卖给了专注于罕见病的瑞典Orphan Biovitrum AB或Sobi 公司；Biosense的董事兼首席执行官，该公司以4亿美元的价格卖给了强生；Cordis公司的首席财务官，该公司被强生以18亿美元的价格收购。他在宾夕法尼亚大学沃顿商学院获得MBA学位，主修医疗管理，并在美国商船学院获得学士学位。
Alfred Novak,has served on Pasithea Therapeutics Corp. Board since September 2022. Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies.Between October 2015 to June 2022, Mr. Novak served as a director of LivaNova Plc (NASDAQ: LIVN), which is a medical device company. From May 2017 to November 2019, Mr. Novak served as a director of Dova Pharmaceuticals, which was sold to Swedish Orphan Biovitrum AB or Sobi, a company focused on rare diseases, for over $900 million; a director and CEO of Biosense, which was sold to Johnson & Johnson for $400 million; and CFO of Cordis Corporation, which was acquired by Johnson & Johnson for $1.8 billion. He received his MBA from the Wharton School of the University of Pennsylvania with a concentration in Healthcare Administration and a BS from the United States Merchant Marine Academy. - Alfred Novak，自2022年9月起担任Pasithea Therapeutics Corp.董事会成员。作为首席执行官和首席财务官，诺瓦克先生拥有丰富的运营经验，曾在多家制药和医疗设备公司的董事会任职。诺瓦克在产品开发、监管审批、商业活动等方面拥有敏锐的财务头脑和广泛的专业知识，并在为股东创造可观价值方面拥有良好的记录。2015年10月至2022年6月，诺瓦克先生担任LivaNova公司（纳斯达克股票代码：LIVN）的董事，该公司是一家医疗设备公司。从2017年5月到2019年11月，诺瓦克担任Dova制药的董事，该公司以超过9亿美元的价格卖给了专注于罕见病的瑞典Orphan Biovitrum AB或Sobi 公司；Biosense的董事兼首席执行官，该公司以4亿美元的价格卖给了强生；Cordis公司的首席财务官，该公司被强生以18亿美元的价格收购。他在宾夕法尼亚大学沃顿商学院获得MBA学位，主修医疗管理，并在美国商船学院获得学士学位。
- Alfred Novak,has served on Pasithea Therapeutics Corp. Board since September 2022. Mr. Novak has broad operating experience as a Chief Executive Officer and Chief Financial Officer and has served on the boards of several pharmaceutical and medical device companies.Between October 2015 to June 2022, Mr. Novak served as a director of LivaNova Plc (NASDAQ: LIVN), which is a medical device company. From May 2017 to November 2019, Mr. Novak served as a director of Dova Pharmaceuticals, which was sold to Swedish Orphan Biovitrum AB or Sobi, a company focused on rare diseases, for over $900 million; a director and CEO of Biosense, which was sold to Johnson & Johnson for $400 million; and CFO of Cordis Corporation, which was acquired by Johnson & Johnson for $1.8 billion. He received his MBA from the Wharton School of the University of Pennsylvania with a concentration in Healthcare Administration and a BS from the United States Merchant Marine Academy.
高管简历
中英对照 | 中文 | 英文- Lawrence Steinman
Lawrence Steinman曾于2016年4月至2020年7月担任BioAtla，LLC的顾问委员会成员，并自2020年7月起担任董事会成员。此前，Steinman博士于2014年4月至2016年5月担任科学顾问。他是斯坦福大学（Stanford University）的神经病学和神经科学、儿科和遗传学教授，在那里他自1980年以来一直担任教授。Steinman博士的研究专注于多发性硬化症（MS）复发和缓解的原因，多发性硬化症是一种抑制脑炎的分子，也是寻找自身免疫性疾病疫苗的关键。迄今为止，Steinman博士已经为MS和1型糖尿病开发了两种抗原特异性疗法，使用DNA疫苗。具体而言，Steinman博士实验室的研究导致了药物Tysabri Natalizumab的开发，该药物用于治疗克罗恩病患者。他的研究获得了许多奖项，并当选为美国国家科学院和美国国家医学科学院院士。Steinman博士于2012年1月至2019年8月担任Atreca，Inc.的董事会成员，该公司是一家生物技术公司，专注于开发用于癌症治疗的新型疗法。Steinman博士在达特茅斯学院（Dartmouth College）获得学士学位，在哈佛大学（Harvard University）获得医学博士学位。
Lawrence Steinman,as served as Co-Executive hairman since the Closing of the Business Combination in November 2020. He also has primary scientific responsibility for 180 Life Sciences Corp. α7nAChR platform. Dr. Steinman served as Co-Chairman of 180 and as a member of its board of directors since April 2019. Prior to joining 180, he served on the Board of Directors of Centocor Biotech, Inc., from 1989 to 1998, the Board of Directors of Neurocine Biosciences from 1997 to 2005, the Board of Directors of Atreca from 2010 – 2019, the Board of Directors of BioAtla, Inc. (NASDAQ:BCAB) from July 2020 to present (he also serves on the Compensation Committee and Nominating and Corporate Governance Committee of BioAtla), the Board of Directors of Tolerion, Inc. from 2013 to 2020 and the Board of Directors of Alpha5 Integrin from November 2020 to June 2022, and the Board of Directors of Pasithea Therapeutics Corp. (NASDAQ:KTTA) from August 2020 to the present. He is currently the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University and previously served as the Chair of the Interdepartmental Program in Immunology at Stanford University Medical School from 2003 to 2011. He is a member of the National Academy of Medicine and the National Academy of Sciences. He also founded the Steinman Laboratory at Stanford University, which is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. He received the Frederic Sasse Award from the Free University of Berlin in 1994, the Sen. Jacob Javits Award from the U.S. Congress from 1988 through 2002, the John Dystel Prize in 2004 from the National MS Society in the U.S., the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011 from the International Federation of MS Societies and the Anthony Cerami Award in Translational Medicine by the Feinstein Institute of Molecular Medicine in 2015. In 2023, he was honored as a Pioneer in Medicine by the Society for Brain Mapping and Therapeutics. He also received an honorary Ph.D. from the Hasselt University in 2008, and from the University of Buenos Aires in 2022. He received his BA (physics) from Dartmouth College in 1968 and his MD from Harvard University in 1973. He also completed a fellowship in chemical immunology at the Weizmann Institute (1974 – 1977) and was an intern and resident at Stanford University Medical School.- Lawrence Steinman曾于2016年4月至2020年7月担任BioAtla，LLC的顾问委员会成员，并自2020年7月起担任董事会成员。此前，Steinman博士于2014年4月至2016年5月担任科学顾问。他是斯坦福大学（Stanford University）的神经病学和神经科学、儿科和遗传学教授，在那里他自1980年以来一直担任教授。Steinman博士的研究专注于多发性硬化症（MS）复发和缓解的原因，多发性硬化症是一种抑制脑炎的分子，也是寻找自身免疫性疾病疫苗的关键。迄今为止，Steinman博士已经为MS和1型糖尿病开发了两种抗原特异性疗法，使用DNA疫苗。具体而言，Steinman博士实验室的研究导致了药物Tysabri Natalizumab的开发，该药物用于治疗克罗恩病患者。他的研究获得了许多奖项，并当选为美国国家科学院和美国国家医学科学院院士。Steinman博士于2012年1月至2019年8月担任Atreca，Inc.的董事会成员，该公司是一家生物技术公司，专注于开发用于癌症治疗的新型疗法。Steinman博士在达特茅斯学院（Dartmouth College）获得学士学位，在哈佛大学（Harvard University）获得医学博士学位。
- Lawrence Steinman,as served as Co-Executive hairman since the Closing of the Business Combination in November 2020. He also has primary scientific responsibility for 180 Life Sciences Corp. α7nAChR platform. Dr. Steinman served as Co-Chairman of 180 and as a member of its board of directors since April 2019. Prior to joining 180, he served on the Board of Directors of Centocor Biotech, Inc., from 1989 to 1998, the Board of Directors of Neurocine Biosciences from 1997 to 2005, the Board of Directors of Atreca from 2010 – 2019, the Board of Directors of BioAtla, Inc. (NASDAQ:BCAB) from July 2020 to present (he also serves on the Compensation Committee and Nominating and Corporate Governance Committee of BioAtla), the Board of Directors of Tolerion, Inc. from 2013 to 2020 and the Board of Directors of Alpha5 Integrin from November 2020 to June 2022, and the Board of Directors of Pasithea Therapeutics Corp. (NASDAQ:KTTA) from August 2020 to the present. He is currently the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University and previously served as the Chair of the Interdepartmental Program in Immunology at Stanford University Medical School from 2003 to 2011. He is a member of the National Academy of Medicine and the National Academy of Sciences. He also founded the Steinman Laboratory at Stanford University, which is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. He received the Frederic Sasse Award from the Free University of Berlin in 1994, the Sen. Jacob Javits Award from the U.S. Congress from 1988 through 2002, the John Dystel Prize in 2004 from the National MS Society in the U.S., the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011 from the International Federation of MS Societies and the Anthony Cerami Award in Translational Medicine by the Feinstein Institute of Molecular Medicine in 2015. In 2023, he was honored as a Pioneer in Medicine by the Society for Brain Mapping and Therapeutics. He also received an honorary Ph.D. from the Hasselt University in 2008, and from the University of Buenos Aires in 2022. He received his BA (physics) from Dartmouth College in 1968 and his MD from Harvard University in 1973. He also completed a fellowship in chemical immunology at the Weizmann Institute (1974 – 1977) and was an intern and resident at Stanford University Medical School.
- Daniel Schneiderman
丹尼尔·施奈德曼于2020年1月2日被任命为我们的首席财务官。在加入我们之前，Schneiderman先生于2018年11月至2019年12月担任ENXTPA:ALbps Biophytis SA及其美国子公司Biophytis，Inc.的首席财务官，该公司是一家总部位于欧洲的临床阶段生物技术公司，专注于开发与年龄有关的疾病的候选药物，主要专注于神经肌肉疾病。从2012年2月到2018年8月，Schneiderman先生担任Metastat，Inc.（OTCQB:MTST）的财务Vice President，财务总监兼秘书，该公司是一家公开上市的生物技术公司，专注于RX/DX精密医疗解决方案，以治疗侵袭性（转移性）癌症患者。Schneiderman从2008年到2012年2月担任Burnham Hill Partners LLC（一家精品投资银行，提供融资、咨询和商业银行服务）投资银行业务Vice President。Schneiderman从2004年到2008年担任多个职位并承担越来越多的责任，包括担任Pali Capital，Inc.旗下Burnham Hill Partners投资银行业务Vice President。此前，Schneiderman先生于2004年在H.C.Wainwright&Co.，Inc.工作，担任投资银行分析师。Schneiderman先生拥有杜兰大学（Tulane University）经济学学士学位。
Daniel Schneiderman,is a seasoned finance executive with over 20 years of experience in the areas of capital markets and finance operations. Mr. Schneiderman has served as Pasithea Therapeutics Corp. Chief Financial Officer since October 11, 2022 and as a consultant to the Company from July 1, 2022 through October 10, 2022. Prior to joining the Company, from January 2020 through February 2022 Mr. Schneiderman served as Chief Financial Officer of First Wave BioPharma, Inc. (Nasdaq: FWBI), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Prior to joining First Wave, from November 2018 through December 2019, Mr. Schneiderman served as Chief Financial Officer of Biophytis SA, (ENXTPA: ALBPS; Nasdaq: BPTS) and its U.S. subsidiary, Biophytis, Inc., a European-based, clinical-stage biotechnology company focused on the development of drug candidates for age-related diseases, with a primary focus on neuromuscular diseases. From February 2012 through August 2018, Mr. Schneiderman served as Vice President of Finance, Controller and Secretary of MetaStat, Inc. (OTCQB: MTST), a publicly traded biotechnology company with a focus on Rx/Dx precision medicine solutions to treat patients with aggressive (metastatic) cancer. From 2008 through February 2012, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners LLC, a boutique investment bank providing capital raising, advisory and merchant banking services primarily in the healthcare and biotechnology industries. From 2004 through 2008, Mr. Schneiderman served in various roles and increasing responsibilities, including as Vice President of Investment Banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, Mr. Schneiderman worked at H.C. Wainwright & Co., Inc. in 2004 as an investment banking analyst. Mr. Schneiderman holds a bachelor's degree in economics from Tulane University.- 丹尼尔·施奈德曼于2020年1月2日被任命为我们的首席财务官。在加入我们之前，Schneiderman先生于2018年11月至2019年12月担任ENXTPA:ALbps Biophytis SA及其美国子公司Biophytis，Inc.的首席财务官，该公司是一家总部位于欧洲的临床阶段生物技术公司，专注于开发与年龄有关的疾病的候选药物，主要专注于神经肌肉疾病。从2012年2月到2018年8月，Schneiderman先生担任Metastat，Inc.（OTCQB:MTST）的财务Vice President，财务总监兼秘书，该公司是一家公开上市的生物技术公司，专注于RX/DX精密医疗解决方案，以治疗侵袭性（转移性）癌症患者。Schneiderman从2008年到2012年2月担任Burnham Hill Partners LLC（一家精品投资银行，提供融资、咨询和商业银行服务）投资银行业务Vice President。Schneiderman从2004年到2008年担任多个职位并承担越来越多的责任，包括担任Pali Capital，Inc.旗下Burnham Hill Partners投资银行业务Vice President。此前，Schneiderman先生于2004年在H.C.Wainwright&Co.，Inc.工作，担任投资银行分析师。Schneiderman先生拥有杜兰大学（Tulane University）经济学学士学位。
- Daniel Schneiderman,is a seasoned finance executive with over 20 years of experience in the areas of capital markets and finance operations. Mr. Schneiderman has served as Pasithea Therapeutics Corp. Chief Financial Officer since October 11, 2022 and as a consultant to the Company from July 1, 2022 through October 10, 2022. Prior to joining the Company, from January 2020 through February 2022 Mr. Schneiderman served as Chief Financial Officer of First Wave BioPharma, Inc. (Nasdaq: FWBI), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Prior to joining First Wave, from November 2018 through December 2019, Mr. Schneiderman served as Chief Financial Officer of Biophytis SA, (ENXTPA: ALBPS; Nasdaq: BPTS) and its U.S. subsidiary, Biophytis, Inc., a European-based, clinical-stage biotechnology company focused on the development of drug candidates for age-related diseases, with a primary focus on neuromuscular diseases. From February 2012 through August 2018, Mr. Schneiderman served as Vice President of Finance, Controller and Secretary of MetaStat, Inc. (OTCQB: MTST), a publicly traded biotechnology company with a focus on Rx/Dx precision medicine solutions to treat patients with aggressive (metastatic) cancer. From 2008 through February 2012, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners LLC, a boutique investment bank providing capital raising, advisory and merchant banking services primarily in the healthcare and biotechnology industries. From 2004 through 2008, Mr. Schneiderman served in various roles and increasing responsibilities, including as Vice President of Investment Banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, Mr. Schneiderman worked at H.C. Wainwright & Co., Inc. in 2004 as an investment banking analyst. Mr. Schneiderman holds a bachelor's degree in economics from Tulane University.
- Tiago Reis Marques
Tiago Reis Marques自2020年8月起担任我们的董事会成员和首席执行官。他是伦敦帝国理工学院（Imperial College London）的高级临床研究员，伦敦大学国王学院（King&s College London）的讲师。IPPN在心理学和精神病学方面被《美国新闻》（US News）和最佳全球大学评为全球第二，是世界上最大的神经科学研究中心之一。Marques医生也是莫德斯利医院的精神病学家。他的研究主要集中在精神药物的作用机制和新的治疗靶点。在他的职业生涯中，他的研究获得了多个奖项。Marques博士是精神病学和神经科学同行评审期刊上100多种科学出版物的作者或合著者，曾合著国际治疗指南和著作章节，包括该领域的领先著作《精神疾病的神经生物学》。”.
Tiago Reis Marques has served on our board of directors and as Chief Executive Officer since August 2020. He is a senior clinical fellow at Imperial College London and a lecturer at the IoPPN, King’s College London. IoPPN is ranked second in the world for psychology and psychiatry by US News and Best Global Universities, and is home to one of the world’s largest centers for neuroscience research. Dr. Marques is also a psychiatrist at Maudsley Hospital. His research focuses on topics including the mechanism of action of psychiatric medication and novel treatment targets. During his career, he has obtained multiple awards for his research. Dr. Marques is an author or co-author of more than 100 scientific publications in peer-reviewed journals in psychiatry and neuroscience, has co-authored international treatment guidelines and written book chapters, including in the leading book in the field, “Neurobiology of Mental Illness.”.- Tiago Reis Marques自2020年8月起担任我们的董事会成员和首席执行官。他是伦敦帝国理工学院（Imperial College London）的高级临床研究员，伦敦大学国王学院（King&s College London）的讲师。IPPN在心理学和精神病学方面被《美国新闻》（US News）和最佳全球大学评为全球第二，是世界上最大的神经科学研究中心之一。Marques医生也是莫德斯利医院的精神病学家。他的研究主要集中在精神药物的作用机制和新的治疗靶点。在他的职业生涯中，他的研究获得了多个奖项。Marques博士是精神病学和神经科学同行评审期刊上100多种科学出版物的作者或合著者，曾合著国际治疗指南和著作章节，包括该领域的领先著作《精神疾病的神经生物学》。”.
- Tiago Reis Marques has served on our board of directors and as Chief Executive Officer since August 2020. He is a senior clinical fellow at Imperial College London and a lecturer at the IoPPN, King’s College London. IoPPN is ranked second in the world for psychology and psychiatry by US News and Best Global Universities, and is home to one of the world’s largest centers for neuroscience research. Dr. Marques is also a psychiatrist at Maudsley Hospital. His research focuses on topics including the mechanism of action of psychiatric medication and novel treatment targets. During his career, he has obtained multiple awards for his research. Dr. Marques is an author or co-author of more than 100 scientific publications in peer-reviewed journals in psychiatry and neuroscience, has co-authored international treatment guidelines and written book chapters, including in the leading book in the field, “Neurobiology of Mental Illness.”.
- Daniel Schneiderman
- 暂无中文简介
Daniel Schneiderman,is a seasoned finance executive with over 20 years of experience in the areas of capital markets and finance operations. Mr. Schneiderman has served as Pasithea Therapeutics Corp. Chief Financial Officer since October 11, 2022 and as a consultant to the Company from July 1, 2022 through October 10, 2022. Prior to joining the Company, from January 2020 through February 2022 Mr. Schneiderman served as Chief Financial Officer of First Wave BioPharma, Inc. (Nasdaq: FWBI), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Prior to joining First Wave, from November 2018 through December 2019, Mr. Schneiderman served as Chief Financial Officer of Biophytis SA, (ENXTPA: ALBPS; Nasdaq: BPTS) and its U.S. subsidiary, Biophytis, Inc., a European-based, clinical-stage biotechnology company focused on the development of drug candidates for age-related diseases, with a primary focus on neuromuscular diseases. From February 2012 through August 2018, Mr. Schneiderman served as Vice President of Finance, Controller and Secretary of MetaStat, Inc. (OTCQB: MTST), a publicly traded biotechnology company with a focus on Rx/Dx precision medicine solutions to treat patients with aggressive (metastatic) cancer. From 2008 through February 2012, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners LLC, a boutique investment bank providing capital raising, advisory and merchant banking services primarily in the healthcare and biotechnology industries. From 2004 through 2008, Mr. Schneiderman served in various roles and increasing responsibilities, including as Vice President of Investment Banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, Mr. Schneiderman worked at H.C. Wainwright & Co., Inc. in 2004 as an investment banking analyst. Mr. Schneiderman holds a bachelor's degree in economics from Tulane University. - 暂无中文简介
- Daniel Schneiderman,is a seasoned finance executive with over 20 years of experience in the areas of capital markets and finance operations. Mr. Schneiderman has served as Pasithea Therapeutics Corp. Chief Financial Officer since October 11, 2022 and as a consultant to the Company from July 1, 2022 through October 10, 2022. Prior to joining the Company, from January 2020 through February 2022 Mr. Schneiderman served as Chief Financial Officer of First Wave BioPharma, Inc. (Nasdaq: FWBI), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. Prior to joining First Wave, from November 2018 through December 2019, Mr. Schneiderman served as Chief Financial Officer of Biophytis SA, (ENXTPA: ALBPS; Nasdaq: BPTS) and its U.S. subsidiary, Biophytis, Inc., a European-based, clinical-stage biotechnology company focused on the development of drug candidates for age-related diseases, with a primary focus on neuromuscular diseases. From February 2012 through August 2018, Mr. Schneiderman served as Vice President of Finance, Controller and Secretary of MetaStat, Inc. (OTCQB: MTST), a publicly traded biotechnology company with a focus on Rx/Dx precision medicine solutions to treat patients with aggressive (metastatic) cancer. From 2008 through February 2012, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners LLC, a boutique investment bank providing capital raising, advisory and merchant banking services primarily in the healthcare and biotechnology industries. From 2004 through 2008, Mr. Schneiderman served in various roles and increasing responsibilities, including as Vice President of Investment Banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, Mr. Schneiderman worked at H.C. Wainwright & Co., Inc. in 2004 as an investment banking analyst. Mr. Schneiderman holds a bachelor's degree in economics from Tulane University.
- Graeme Currie
Graeme Currie，自2022年6月起担任Pasithea Therapeutics Corp.首席开发官。Currie博士在制药和生物技术公司拥有30多年的药物开发经验。柯里博士于2021年1月至2022年6月担任Alpha5Integrin LLC的首席执行官。在此之前的2019年至2021年1月，他是Tolerion Inc. LLC的首席开发官。从2017年到2019年，柯里博士是Rainier Therapeutics的首席运营官。柯里博士曾就读于索尔福德大学，在那里他获得了化学和生物化学理学士学位，并在阿斯顿大学获得了DNA甲基化博士学位。
Graeme Currie,has served as Pasithea Therapeutics Corp. Chief Development Officer since June 2022. Dr. Currie has over 30 years of drug development experience in both pharmaceutical and biotechnology companies. Dr. Currie was Chief Executive Officer of Alpha5Integrin LLC from January 2021 to June 2022. Prior to that, from 2019 to January 2021, he was Chief Development Officer of Tolerion Inc. LLC. From 2017 to 2019, Dr. Currie was Chief Operating Officer of Rainier Therapeutics. Dr. Currie attended the University of Salford, where he received his Bachelor of Science in Chemistry and Biochemistry, and Aston University, where he received his PhD in DNA methylation.- Graeme Currie，自2022年6月起担任Pasithea Therapeutics Corp.首席开发官。Currie博士在制药和生物技术公司拥有30多年的药物开发经验。柯里博士于2021年1月至2022年6月担任Alpha5Integrin LLC的首席执行官。在此之前的2019年至2021年1月，他是Tolerion Inc. LLC的首席开发官。从2017年到2019年，柯里博士是Rainier Therapeutics的首席运营官。柯里博士曾就读于索尔福德大学，在那里他获得了化学和生物化学理学士学位，并在阿斯顿大学获得了DNA甲基化博士学位。
- Graeme Currie,has served as Pasithea Therapeutics Corp. Chief Development Officer since June 2022. Dr. Currie has over 30 years of drug development experience in both pharmaceutical and biotechnology companies. Dr. Currie was Chief Executive Officer of Alpha5Integrin LLC from January 2021 to June 2022. Prior to that, from 2019 to January 2021, he was Chief Development Officer of Tolerion Inc. LLC. From 2017 to 2019, Dr. Currie was Chief Operating Officer of Rainier Therapeutics. Dr. Currie attended the University of Salford, where he received his Bachelor of Science in Chemistry and Biochemistry, and Aston University, where he received his PhD in DNA methylation.